(Q35581001)

9 August 2017

1 reference

title

Management of bone loss in men with prostate cancer (English)

1 reference

9 August 2017

Management of Bone Loss in Men With Prostate Cancer (English)

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

31 March 2024

1 reference

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

31 March 2024

1

Celestia S. Higano

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14610412

31 March 2024

language of work or name

English

0 references

publication date

1 December 2003

1 reference

full work available at URL

9 August 2017

http://api.elsevier.com/content/article/PII:S0022534701682582?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

http://api.elsevier.com/content/article/PII:S0022534701682582?httpAccept=text/plain

31 March 2024

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

http://www.jurology.com/doi/pdf/10.1097/01.ju.0000097351.48848.1f

31 March 2024

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

31 March 2024

1 reference

9 August 2017

volume

170

1 reference

9 August 2017

issue

6 Pt 2

1 reference

9 August 2017

page(s)

S59-63; discussion S64

1 reference

9 August 2017

1

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Influence of age and body weight on spine and femur bone mineral density in U.S. white men.

31 March 2024

3

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Vertebral deformity in men

31 March 2024

5

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Epidemiology of osteoporosis

31 March 2024

6

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Clinical review 24: Androgens in the aging male

31 March 2024

7

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Identification of androgen receptors in normal human osteoblast-like cells

31 March 2024

8

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Sex steroids and bone mass in older men. Positive associations with serum estrogens and negative associations with androgens

31 March 2024

9

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Epidemiology of hip fractures in the elderly: a cross-national analysis of mortality rates for femoral neck fractures.

31 March 2024

12

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Risk factors for spinal osteoporosis in men

31 March 2024

13

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Do men and women fracture bones at similar bone densities?

31 March 2024

14

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Diagnosis of osteoporosis and assessment of fracture risk

31 March 2024

15

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

The prevalence of osteoporosis: gender and racial comparison

31 March 2024

16

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Implications in the use of T-scores for the diagnosis of osteoporosis in men

31 March 2024

17

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Utility of heel ultrasound bone density in men.

31 March 2024

18

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Alendronate for the Treatment of Osteoporosis in Men

31 March 2024

19

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Tolerability of once-weekly alendronate in patients with osteoporosis: a randomized, double-blind, placebo-controlled study

31 March 2024

20

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group

31 March 2024

21

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis

31 March 2024

22

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

A randomized trial of nasal spray salmon calcitonin in men with idiopathic osteoporosis: effects on bone mineral density and bone markers

31 March 2024

23

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Castrated men exhibit bone loss: effect of calcitonin treatment on biochemical indices of bone remodeling.

31 March 2024

24

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Prevention of bone loss with risedronate in glucocorticoid-treated rheumatoid arthritis patients

31 March 2024

25

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Corticosteroid osteoporosis

31 March 2024

26

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Risedronate increases bone density and reduces vertebral fracture risk within one year in men on corticosteroid therapy

31 March 2024

27

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Alendronate for the prevention of bone loss in patients on inhaled steroid therapy

31 March 2024

28

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Longitudinal effects of aging on serum total and free testosterone levels in healthy men. Baltimore Longitudinal Study of Aging

31 March 2024

29

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Low bone mineral density in hormone-naïve men with prostate carcinoma

31 March 2024

30

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Androgen deprivation therapy for prostate cancer results in significant loss of bone density

31 March 2024

32

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Progressive osteoporosis during androgen deprivation therapy for prostate cancer

31 March 2024

34

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

The effect of combined androgen blockade on bone turnover and bone mineral densities in men treated for prostate carcinoma: longitudinal evaluation and response to intermittent cyclic etidronate therapy

31 March 2024

35

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Progressive decrease in bone density over 10 years of androgen deprivation therapy in patients with prostate cancer.

31 March 2024

36

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

The antiosteoporotic efficacy of intravenous pamidronate in men with prostate carcinoma receiving combined androgen blockade: a double blind, randomized, placebo-controlled crossover study

31 March 2024

37

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer

31 March 2024

38

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Incidence of bone fracture in patients receiving luteinizing hormone-releasing hormone agonists for prostate cancer

31 March 2024

40

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

What does prostate-specific antigen recurrence mean?

31 March 2024

41

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Natural history of progression after PSA elevation following radical prostatectomy

31 March 2024

42

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group

31 March 2024

43

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

31 March 2024

44

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Screening and early hormonal treatment of prostate cancer are accumulating strong evidence and support

31 March 2024

46

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens

31 March 2024

47

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Diethylstilbestrol in treatment of postorchiectomy vasomotor symptoms and its relationship with serum follicle-stimulating hormone, luteinizing hormone, and testosterone

31 March 2024

48

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Transdermal estrogen in the treatment of hot flushes in men with prostate cancer

31 March 2024

49

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Treatment of castration-induced menopausal symptoms with low dose diethylstilbestrol in men with advanced prostate cancer

31 March 2024

51

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older

31 March 2024

52

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

31 March 2024

53

1 reference

https://api.crossref.org/works/10.1097/01.JU.0000097351.48848.1F

31 March 2024

Identifiers

1 reference

9 August 2017

1 reference